Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma

Abstract Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in t...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2019-02, Vol.21 (3), p.296-305
Main Authors: Grommes, Christian, Rubenstein, James L, DeAngelis, Lisa M, Ferreri, Andres J M, Batchelor, Tracy T
Format: Article
Language:English
Subjects:
Age Factors
Antineoplastic Agents, Alkylating - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Burkitt Lymphoma - diagnostic imaging
Burkitt Lymphoma - epidemiology
Burkitt Lymphoma - pathology
Burkitt Lymphoma - therapy
Central Nervous System Neoplasms - diagnostic imaging
Central Nervous System Neoplasms - epidemiology
Central Nervous System Neoplasms - pathology
Central Nervous System Neoplasms - therapy
Chemoradiotherapy
Cranial Irradiation - adverse effects
Cranial Irradiation - methods
Cytoreduction Surgical Procedures
Humans
Immunocompromised Host
Invited Review
Lymphoma, Large B-Cell, Diffuse - diagnostic imaging
Lymphoma, Large B-Cell, Diffuse - epidemiology
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Large B-Cell, Diffuse - therapy
Lymphoma, T-Cell - diagnostic imaging
Lymphoma, T-Cell - epidemiology
Lymphoma, T-Cell - pathology
Lymphoma, T-Cell - therapy
Methotrexate - administration & dosage
Neoplasm Staging
Neurosurgical Procedures
Prognosis
Rituximab - administration & dosage
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Despite this progress, durable remission is recorded in only 50% of patients, and therapy can be associated with significant late neurotoxicity. Here, we overview the epidemiology, clinical presentation, staging evaluation, prognosis, and current up-to-date treatment of immunocompetent PCNSL patients.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noy192